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Sarcopenic obesity and risk of new onset depressive symptoms
in older adults: English Longitudinal Study of Ageing
M Hamer, GD Batty and M Kivimaki
BACKGROUND:We examined the role of sarcopenic obesity as a risk factor for new-onset depressive symptoms over 6-year follow-
up in a large sample of older adults.
METHODS: The sample comprised 3862 community dwelling participants (1779 men, 2083 women; mean age 64.6 ± 8.3 years)
without depressive symptoms at baseline, recruited from the English Longitudinal Study of Ageing. At baseline and 4-year follow-
up, handgrip strength (kg) of the dominant hand was assessed using a hand-held dynamometer, as a measure of sarcopenia. The
outcome was new onset depressive symptoms at 6-year follow-up, deﬁned as a score of ⩾ 4 on the 8-item Centre of
Epidemiological Studies Depression scale. Sarcopenic obesity was deﬁned as obese individuals (body mass index ⩾ 30 kgm−2) in
the lowest tertile of sex-speciﬁc grip strength (o35.3 kg men; o19.6 kg women).
RESULTS: Using a multivariable logistic regression model, the risk of depressive symptoms was greatest in obese adults in the
lowest tertile of handgrip strength (odds ratio (OR), 1.79, 95% conﬁdence interval (CI), 1.10, 2.89) compared with non-obese
individuals with high handgrip strength. Participants who were obese at baseline and had a decrease of more than 1 s.d. in grip
strength over 4-year follow-up were at greatest risk of depressive symptoms (OR= 1.97, 95% CI, 1.22, 3.17) compared with non-
obese with stable grip strength.
CONCLUSIONS: A reduction in grip strength was associated with higher risk of depressive symptoms in obese participants only,
suggesting that sarcopenic obesity is a risk factor for depressive symptoms.
International Journal of Obesity advance online publication, 8 September 2015; doi:10.1038/ijo.2015.124
INTRODUCTION
The association between two disorders of major public health
importance, obesity and mental health, remains unclear.1–6
A recent meta-analysis containing prospective cohort studies
showed an association between body mass index (BMI) and risk of
depressive symptoms,1 although some individual studies have
found no association2 and others suggest that greater body
weight may actually confer protection against future mental
health problems and suicide.3,4 Furthermore, the discordant
results remain unclear when using an unconfounded instrument
variable for obesity (adiposity-related genetic variants).5,6
Different obesity phenotypes may exist,7 and in particular
variation in skeletal muscle mass across obese individuals may
confer different health risks.8 Sarcopenia, a syndrome character-
ized by a progressive loss of skeletal muscle mass and quality (or
strength) resulting in impaired physical performance, is related to
an increased risk of physical disability, poor quality of life and
death.9 Sarcopenic obesity, a co-occurrence of low muscle
strength and excess body fat, is an emerging clinical entity in
which these two states are thought to act in negative synergism in
the pathophysiology of both metabolic, functional impairments
and mortality risk.8,10–17 Although sarcopenia appears to be
associated with cognitive impairment and depressive symptoms
in the few studies conducted,18,19 these were small in scale
(resulting in modest statistical power), based on non-
representative samples (reducing generalisablity) and, most
importantly, cross-sectional (hampering insights into the direc-
tionality of any relationships).
The aim of this study was to examine the role of sarcopenic
obesity as a risk factor for new-onset depressive symptoms over
6-year follow-up in a large, well characterized, general population-
based sample of older adults. Since the skeletal muscle is known
to have a role in various metabolic responses, we hypothesised
sarcopenia could adversely affect mental function via metabolic
and endocrine mechanisms. Our hypothesis was that obesity and
sarcopenia in combination are associated with a greater depres-
sion risk than either of the disorders alone.
MATERIALS AND METHODS
Study sample and procedures
The English Longitudinal Study of Ageing is an ongoing cohort study of a
nationally representative sample of the English population born on or
before 29 February 1952 living in private households.20 A multistage
stratiﬁed probability sampling method using postcode sectors and
household addresses was used to recruit the sample. Participants gave
full, informed written consent to take part in the study and ethical approval
was obtained from the London Multicentre Research Ethics Committee. For
the purposes of the present analyses, data collected in 2004/05 (wave 2)
were used as the baseline, as this was the ﬁrst occasion on which clinical
information was gathered, and follow-up for new cases of depression was
performed in 2010/11. The inclusion criteria were absence of depression at
baseline and availability of exposure, outcome and covariate data. For the
key exposure measure, grip strength, there were no upper age limits
although respondents were excluded if they had swelling or inﬂammation,
severe pain or a recent injury or surgery to the hand in the preceding
6 months. Data on the key exposure variables at baseline were available in
7055 participants, although 557 were excluded at baseline with depressive
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symptoms, a further 2028 were lost to follow-up (due to death, emigration,
institutionalisation), and 608 participants had missing data on covariables
or outcome. Thus, the ﬁnal analytic sample consisted of 3862 individuals.
Measures
Exposure. Handgrip strength (kg) of the dominant hand was assessed
using the Smedley hand-held dynamometer (Stoelting Co, IL, USA ), using
the average of three measurements. Participants were required to hold the
device at a right angle to their body and exert maximum force for a couple
of seconds when instructed. Successive trials were alternated between
dominant and non-dominant hands. Nurses measured participants’ body
weight to the nearest 0.1 kg using Tanita electronic scales (Tanita Co, IL,
USA) without shoes and in light clothing, and height was measured using a
Stadiometer with the Frankfurt plane in the horizontal position; BMI was
calculated using the standard formula (weight (kg)/height2 (m2)). Clinical
data were collected in wave 2 (2004/5) and wave 4 (2008/9) that also
allowed us to examine changes in grip strength and body mass.
Covariables. At baseline, trained interviewers collected information on
psychosocial, demographic and health-related factors. These questions
included self-reported cigarette smoking (current, previous or non-
smoker), the self-reported frequency of participation in vigorous, moderate
and light physical activities (more than once per week, once per week, one
to three times per month, hardly ever), self-reported frequency of alcohol
intake (daily, 5 to 6/week, 3 to 4/week, 1 to 2/week, 1 to 2/month, once
every couple of months, 1 to 2/year, never) and self-reported physician-
diagnosed medical conditions (cardiovascular diseases, diabetes, cancer,
arthritis). Participants reported new onset of these diseases every 2 years
through follow-up thus we were able to derive a time-varying
accumulative chronic disease variable. Self-reported wealth was used as
our measure of socioeconomic status. The wealth variable comprised the
total value of the participant’s home (excluding mortgage), ﬁnancial assets
such as savings, business assets and physical wealth such as artwork or
jewellery, which has been shown to best capture the material resources
available to older adults.21
Outcome. Depressive symptoms were assessed at baseline and follow-up
using the self-reported 8-item Centre of Epidemiological Studies Depres-
sion scale. As in previous studies, we used a score of ⩾ 4 to deﬁne cases of
elevated depressive symptoms.22 Participants scoring ⩾ 4 at baseline were
excluded from the analyses. The Centre of Epidemiological Studies
Depression is highly validated for use in older adults, displaying excellent
psychometric properties.23,24
Statistical analysis
Several tests were used (χ2 and analysis of variance with Scheffe post-hoc
tests) to examine differences in baseline characteristics with respect to
new onset depressive symptoms. We used multiple logistic regression to
calculate odds ratios (OR) and 95% conﬁdence intervals (CI) for the risk of
new cases of elevated depressive symptoms at follow-up in relation to
obesity and grip strength (individually and in combination). In preliminary
analyses, there was no evidence of effect modiﬁcation according to gender
in the obesity/sarcopenia relation with depressive symptoms; as such, data
for men and women were pooled and gender-adjusted. In order to
examine additive effects of grip strength and obesity, we categorized the
data into sex-speciﬁc tertiles of handgrip strength in relation to obesity1
(non-obese o30 kgm−2 and obese⩾ 30 kgm− 2). In multivariable models
we adjusted for several covariates in a step-wise fashion: Model 1
contained age and sex; and Model 2 contained additional behavioural and
clinical covariates, including smoking, alcohol, physical activity, wealth,
time-varying accumulative chronic disease through follow-up (cardiovas-
cular disease, diabetes, cancer and arthritis). We chose this modelling
strategy a priori based on existing data on obesity and depressive
symptoms.1,22 We performed sensitivity analyses making further adjust-
ment for metabolic risk factors in a sub-sample of participants with
available biomarker data (for a full description of methodology on
biomarker data collection see Hamer et al.22 ). In addition we studied the
association of changes in grip strength with risk of depressive symptoms
using the same modelling strategy described above. All analyses were
conducted using SPSS (version 20, Chicago, IL, USA).
RESULTS
The analytic sample comprised 3862 study participants (1779 men,
2083 women; mean age at baseline 64.6 ± 8.3 years). In
comparison with the overall baseline sample (excluding partici-
pants removed with depression), the sub-group used in the
present analyses were younger (68.9 vs 64.6 years, Po0.001), had
higher mean grip strength (28.3 vs 30.4 kg, Po0.001), and better
health behaviours including lower rates of smoking (19.1 vs 14.8%,
Po0.001) and greater physical activity (23.0 vs 32.6%, Po0.001,
vigorously active ⩾ 1/week). Although these differences are
statistically signiﬁcant, the absolute difference was small. At
6-year follow-up, there were 328 people with new onset elevated
depressive symptoms. In Table 1 we show the characteristics of
study participants according to newly developed depression
symptoms. Study members with depressive symptoms tended to
be older, female, smokers, less physically active, less likely to
consume alcohol on a daily basis, be of lower socioeconomic
status and have higher prevalence of major chronic somatic
diseases.
In models in which ORs were adjusted for multiple covariates
(including multiple adjustment for grip strength/obesity depend-
ing on the predictor in question), each unit increase in baseline
grip strength was associated with lower risk of depressive
Table 1. The characteristics of participants according to new onset depressive symptoms at 6-year follow-up
Status at follow-upa
Non-depressed (n=3534) Depressive symptoms (n= 328) P-value for difference
Age at baseline 64.4± 8.2 66.5± 8.7 o0.001
Sex (%men) 1654 (46.8) 124 (37.8) o0.001
Cigarette smokers (%) 466 (13.2) 66 (20.1) o0.001
Vigorous physical activity (%) 1251 (35.4) 78 (23.8) o0.001
Regular alcohol intake (% daily) 887 (25.1) 78 (23.8) 0.042
Wealth (% in highest quintile) 997 (28.2) 60 (18.3) o0.001
Prevalent diseaseb (%)
Cardiovascular disease/diabetes 1202 (34.0) 158 (48.2) o0.001
Cancer 399 (11.3) 54 (16.5) 0.002
Arthritis 1467 (41.5) 180 (54.9) o0.001
Grip strength (kg) 31.2± 11.2 27.4± 10.5 o0.001
Body mass index (kgm− 2) 27.8± 4.7 28.6± 5.4 0.004
aAll participants were free of depressive symptoms at baseline. bAccumulative prevalence from baseline through follow-up. Data presented as mean ± s.d.
unless otherwise stated.
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symptoms (OR = 0.98, 95% CI, 0.96–0.99; P= 0.018) while obesity
was related to an elevated risk (OR = 1.32, 95% CI, 1.03–1.71;
P= 0.032).
Compared with non-obese participants with high handgrip
strength (our referent group because we anticipated the lowest
risk within it), non-obese participants with low handgrip strength
experienced an increased risk of depressive symptoms, but the
effect estimate was markedly attenuated after multiple adjust-
ments (Table 2). The risk of depressive symptoms in obese adults
with low handgrip strength was 1.79 (95% CI, 1.10, 2.89) times
greater compared to non-obese individuals with high handgrip
strength after multivariate adjustment. Obese participants with
high and intermediate handgrip strength demonstrated an
increased risk of depressive symptoms, but the effect estimate
was markedly attenuated after multiple adjustments. In further
analyses we removed participants with BMIo18.5 (N= 18)
although results did not differ.
Sensitivity analyses
In a slightly smaller sample with data on grip strength at both
wave 2 and wave 4 (n= 3369) it was possible to examine
associations of changes in these variables with risk of depressive
symptoms. Overall, as anticipated, there was a reduction in grip
strength (−1.91 ± 5.7 kg) over the intervening 4 years such that
19.3% of the sample demonstrated more than 1 s.d. reduction.
The association between baseline obesity and change in handgrip
strength in relation to risk of elevated depressive symptoms at
follow-up is presented in Supplementary Table S1. These analyses
showed that participants who were obese at baseline and had a
decrease of more than 1 s.d. in grip strength were at greatest risk
of depressive symptoms (OR = 1.97, 95% CI, 1.22, 3.17) compared
with non-obese with stable grip strength. In further sensitivity
analyses we made adjustment for metabolic risk factors as
previously described,22 although the pattern of results did not
change (Supplementary Table S2). Lastly, we categorised partici-
pants using Foundation for the National Institutes of Health (FNIH)
sex-speciﬁc handgrip cutoffs (men o26 kg; women o16 kg) for
those at risk of weakness.25 8.6% of the sample met the threshold
for weakness although the pattern of results largely replicated the
original results, showing sarcopenic obese were at the highest risk
of depressive symptoms (Supplementary Table S3).
DISCUSSION
This study demonstrates an association between sarcopenic
obesity and new onset depressive symptoms in older adults.
Hand grip strength, our indicator of sarcopenic loss of muscle
mass, was associated with depressive symptoms, an effect that
was particularly marked in obese participants. In addition, we were
able to show that a reduction in grip strength over 4 years was
associated with higher risk of depressive symptoms in obese
participants only. Although several small cross-sectional studies
have shown associations of sarcopenia with cognitive impairment
and depressive symptoms,18,19 this is the ﬁrst study to examine
this issue in obese and non-obese adults longitudinally.
There have been inconsistencies in the pattern of ﬁndings
across studies relating obesity to mental health outcomes.1–6 We
have previously demonstrated that the risk of depressive
symptoms is greatest when obesity is combined with an adverse
metabolic proﬁle—’metabolically unhealthy obesity’.22,26 The
skeletal muscle is known to have a role in various metabolic
responses, thus sarcopenia could adversely affect mental function
via metabolic and endocrine mechanisms. For example, skeletal
muscle represents a major organ for glucose homeostasis,
responsible for up to 75% of post-prandial (that is, insulin-
stimulated) glucose uptake.27 Low muscle mass might therefore
be expected to impair glucose homeostasis and various studies
have shown a link between glycaemic control and
depression.28–30 In previous work on obese adolescents with type
2 diabetes, brain abnormalities, such as reduced white matter
volume and enlarged cerebrospinal ﬂuid space, have been found,
which might result from changes in vascular function and glucose
abnormalities.31
As expected, women were more likely to report new onset
depressive symptoms than men (covariate adjusted OR= 1.34,
95% CI, 1.04, 1.73). It has been suggested that women may reach a
threshold for sarcopenia faster than men, thus the impact of
obesity on women may be exaggerated.17 This notwithstanding,
we found no interaction between muscle strength and sex in
relation to new onset depressive symptoms, thus the sex
differences may be attributable to other underlying mechanisms.
Presently, there is no consensus on the deﬁnition of ‘sarcopenic
obesity’. Indeed, the prevalence of sarcopenic obesity depends on
the deﬁnitions used, and differs considerably when sarcopenia is
deﬁned using handgrip strength,13,14 muscle mass11,15 or midarm
muscle circumference.16 We used handgrip strength as an
indicator of sarcopenic loss of muscle mass. Although lean mass
and strength (muscle quality) may not decline at the same rate,
loss of lean mass is strongly associated with strength decline in
both men and women.32 The clinical relevance of both measure-
ments is reﬂected in the revised deﬁnition of sarcopenia to
incorporate a functional component, that is, to include low muscle
strength (muscle quality).9 For practical reasons, longitudinal
measurements collected in this cohort did not extend to
quantiﬁcation of skeletal muscle mass, but considering the above
deﬁnition, low handgrip strength might be considered to be
equally clinically relevant as formal measurements of low muscle
mass. The use of BMI to deﬁne obesity in the context of sarcopenia
is a further limitation since changes in BMI might partly reﬂect
alterations in lean muscle mass with ageing. English Longitudinal
Study of Ageing is designed to be a nationally representative
cohort, although the present sample included younger and
healthier participants than the overall cohort due to loss of older,
more disadvantaged men and women over follow up. Thus the
present ﬁndings might reﬂect a conservative estimate of the true
effects.
In summary we demonstrate, for the ﬁrst time, an association
between sarcopenia and new onset depressive symptoms that
was particularly marked in obese participants. A reduction in grip
strength over 4 years was associated with higher risk of depressive
Table 2. Odds ratios (95% CI) for the association of handgrip strength
and obesity at baseline with the risk of new onset elevated depressive
symptoms at 6-year follow-up (n= 3862)
Handgrip
strengtha
Cases/
participants at
risk
Model 1
odds ratio
(95% CI)
Model 2
odds ratio
(95% CI)
Non-obese participants (N = 2780)
High 51/972 1.00 (reference) 1.00 (reference)
Intermediate 76/1010 1.42 (0.98, 2.06) 1.28 (0.87, 1.87)
Low 82/798 1.83 (1.24, 2.70) 1.47 (0.98, 2.20)
Obese participants (N = 1082)
High 36/423 1.72 (1.11, 2.69) 1.39 (0.88, 2.20)
Intermediate 44/389 2.19 (1.43, 3.35) 1.65 (1.06, 2.58)
Low 39/270 2.60 (1.64, 4.10) 1.79 (1.10, 2.89)
Abbreviation: CI, conﬁdence interval. Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, physical activity, smoking, alcohol, wealth,
time varying accumulative cardiovascular disease (angina, heart disease,
heart failure, heart murmur, arrhythmia and stroke), diabetes, cancer and
arthritis. aIn men, the range of handgrip strength at baseline was 4–35.3,
35.4–44.2, 444.2 kg for low, intermediate and high tertiles, respectively.
The corresponding ranges in women were 4–19.6, 19.7–24.9, 424.9 kg,
respectively.
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symptoms in obese participants only, providing further evidence
for sarcopenic obesity and risk of depressive symptoms. Further
research is needed to determine whether interventions to
maintain muscle quality would reduce depression risk in obese
older adults.
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